Novo Nordisk's recent judicial victory empowers it to challenge misleading marketing by a compounding pharmacy, reinforcing patent protection for its GLP-1 weight-loss drugs. However, despite this strengthened defense, the company's stock remains stagnant due to lack of momentum and muted market sentiment, prompting a cautious approach from investors until clearer catalysts emerge.